Individuals at risk of anaphylaxis—an acute systemic hypersensitivity reaction to an allergen or trigger, typically associated with skin reactions, nausea/vomiting, difficulty breathing, and shock—are ...

Please provide your email address to receive an email when new articles are posted on . Epinephrine autoinjectors may have little effect on surviving anaphylaxis events. Research is needed in ...

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1 HCP survey data ...

In 2021, Governor John Carney signed Senate Bill 55 to expand access to epinephrine auto-injectors — better known by brand name EpiPen — in Delaware colleges and universities. Beginning this fall, the ...

Toronto (CTV Network) — Health Canada has issued a recall for Emerade epinephrine auto-injectors due to possible device failures. “Return your Emerade auto-injector to your pharmacy for a suitable ...

The recent approval of a new epinephrine nasal spray gives patients a powerful new way to keep life-threatening allergic reactions at bay. But that doesn't mean folks no longer have to worry about ...

Epinephrine auto-injectors are the mainstay of emergency treatment for anaphylactic allergic reactions, but despite many years of widespread use, important questions about them remain unanswered. At ...

On June 13, 2019, Connecticut Governor Ned Lamont signed into law Public Act No. 19-19 “An Act Concerning Epinephrine Auto Injectors” (PA 19-19). PA 19-19 went into effect on the same date. This ...

EURneffy offers a portable, needle-free alternative to traditional adrenaline delivery, requires no special storage, and has ...

An adrenaline nasal spray for the emergency treatment of anaphylaxis has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). This marks the first time a needle-free ...

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the ...